Criminalizing Coverage Denials?

What Pennsylvania’s New Bill Reveals About the Growing Backlash Against Health Insurers

By Elena Pak, Credentialing Department, WCH

When Pennsylvania lawmakers introduced House Bill 2611 earlier this month, the proposal immediately attracted national attention—not because it reforms prior authorization, tightens regulatory oversight, or expands consumer appeals rights, but because it targets something far more unusual: the personal criminal liability of health insurance executives.

Under the proposal, chief executive officers of insurance companies could face criminal penalties if a patient suffers serious bodily injury or death following a denial of coverage for a medically necessary service. The bill would create a new category of aggravated assault applicable to insurance company CEOs whose organizations issue adverse benefit determinations that allegedly contribute to catastrophic patient harm.

The legislation is unlikely to become law in its current form. Yet dismissing it as symbolic politics would miss a more important development. The proposal reflects a growing shift in how policymakers, patients, and even some regulators are beginning to frame the consequences of coverage denials—not as administrative disputes, but as decisions with potentially life-altering clinical outcomes.

The real story is not the bill itself. The real story is why lawmakers felt compelled to introduce it.

The frustration behind the legislation

For decades, disputes between patients and insurers have generally been treated as regulatory or contractual matters. If a claim is denied, a patient may appeal. If prior authorization is refused, physicians may seek reconsideration. If a payer violates state requirements, regulators may impose fines or corrective action plans. The Pennsylvania proposal represents a fundamentally different theory of accountability.

Rather than asking whether a denial complied with policy language or utilization management standards, the legislation asks whether executives should bear personal responsibility when denied care allegedly contributes to severe patient harm.

That shift did not emerge in a vacuum. Public frustration with health insurers has intensified as prior authorization requirements have expanded across both commercial and government-sponsored plans. Numerous studies have documented physician concerns that administrative barriers can delay treatment, increase provider burden, and disrupt continuity of care.

At the same time, patients increasingly encounter a healthcare system in which access to treatment often depends not solely on physician judgment but also on payer approval processes.

The result is a growing perception among some policymakers that coverage decisions are no longer merely financial determinations—they are clinical gatekeeping decisions. The Pennsylvania bill translates that frustration into legislation.

Why this proposal is legally extraordinary

While insurers are frequently sued over denied claims, criminal liability is an entirely different matter. The bill would effectively require a legal connection between an adverse benefit determination and subsequent patient injury or death. Establishing such causation would be extraordinarily difficult.

Consider a typical healthcare denial scenario. A payer may deny coverage based on medical necessity criteria. A physician may disagree. The patient may seek an appeal. The patient’s condition may worsen during that process.

Determining whether a particular executive is criminally responsible for that outcome would require proving a chain of causation that involves physicians, utilization management personnel, clinical reviewers, appeals processes, patient decisions, and disease progression.

From a legal standpoint, that threshold is significantly higher than proving that a denial was incorrect. It requires demonstrating that the denial directly contributed to serious harm and that criminal liability should attach to an individual executive rather than the organization itself. That is one reason many legal observers view the bill as unlikely to survive substantial legislative scrutiny even if it advances beyond committee review.

A symptom of a larger policy failure

Although the criminal liability provision has generated headlines, the legislation may be better understood as a symptom of broader dissatisfaction with existing oversight mechanisms. Most states already regulate health insurers through network adequacy standards, external review programs, utilization management requirements, and market conduct examinations.

Pennsylvania itself enacted prior authorization reforms intended to streamline review processes and improve appeals procedures. Those reforms expanded oversight of benefit determinations and strengthened administrative protections for beneficiaries.

Yet despite these frameworks, lawmakers continue to receive complaints from constituents who experience delayed care, unexpected denials, and lengthy appeals processes. The introduction of HB 2611 suggests that some policymakers increasingly view current accountability mechanisms as insufficient.

Whether that perception accurately reflects system performance is a separate question. Politically, however, perception often matters as much as data.

The CEO Question

Perhaps the most notable aspect of the legislation is its focus on chief executive officers. In practice, CEOs rarely participate in individual coverage determinations. Coverage decisions are typically made through complex utilization management systems involving clinical guidelines, medical directors, prior authorization vendors, and appeals structures.

The bill therefore raises an important governance question: Who should be accountable for adverse outcomes associated with coverage decisions?

Supporters argue that executives ultimately shape organizational incentives and therefore should bear responsibility for systemic practices that allegedly prioritize financial performance over patient care. Legislators sponsoring the measure have explicitly framed the issue as one of corporate accountability.

Critics are likely to argue that attaching criminal liability to executives for individual medical outcomes creates a precedent that is both legally problematic and operationally unworkable.

Either way, the proposal reflects growing political willingness to move accountability discussions beyond corporate entities and toward individual leadership. That trend extends well beyond Pennsylvania.

The economics beneath the politics

The bill also highlights a deeper tension at the center of modern healthcare financing. Health insurers are expected to perform two competing functions simultaneously. First, they must ensure that medically necessary services are accessible to members. Second, they must manage costs to keep premiums affordable and maintain financial sustainability. Coverage review systems exist because not every requested service is clinically indicated, evidence-based, or cost-effective.

Yet every denial creates the possibility of conflict between financial stewardship and patient access. The Pennsylvania proposal emerges from a belief among some lawmakers that current incentives tilt too heavily toward cost containment.

Whether that assessment is accurate is less important than the fact that it is gaining political traction. Increasingly, debates that once focused on utilization management procedures are becoming debates about corporate accountability.

What happens next?

The bill has been referred to the Pennsylvania House Judiciary Committee, where it faces significant procedural and political hurdles.  Even if the legislation never advances further, its introduction may prove consequential.

Historically, controversial healthcare proposals often function as signaling mechanisms. They establish negotiating positions that later influence more conventional reforms.

In this case, lawmakers may ultimately pursue measures such as:

• stronger oversight of prior authorization programs;
• expanded reporting requirements for denial rates;
• greater transparency regarding medical necessity criteria;
• enhanced external review protections;
• larger penalties for inappropriate denials.

Those reforms would be far more likely to survive legislative review than criminal penalties directed at insurance executives.

Yet the introduction of HB 2611 signals that policymakers are increasingly willing to consider aggressive interventions if existing oversight frameworks are perceived as ineffective.

The bigger implication

Viewed narrowly, Pennsylvania’s proposal is a controversial criminal liability bill with limited prospects for enactment.

Viewed more broadly, it represents something more significant: a growing political challenge to the traditional assumption that insurance coverage decisions are primarily administrative matters. For decades, policymakers focused on improving appeals processes, refining utilization management rules, and strengthening regulatory oversight.

HB 2611 reflects a different mindset. It suggests that at least some lawmakers are beginning to view coverage denials through the lens of patient harm rather than administrative compliance.

Whether that perspective ultimately leads to meaningful reform remains uncertain. What is becoming increasingly clear, however, is that the public debate around insurance denials is changing. The question is no longer simply whether insurers followed the rules.

The question increasingly being asked is whether the rules themselves create adequate accountability when denied care contributes to adverse patient outcomes.

Sources

1. Pennsylvania House of Representatives. “Kinkead, Friel Launch Bill to Hold Healthcare Executives Accountable.” June 2026.
2. Pennsylvania House Bill 2611 Legislative Summary. FastDemocracy Legislative Tracking. June 2026.
3. Becker’s Payer Issues. “Pennsylvania Prior Authorization Reform Bill Signed Into Law.” Background on Pennsylvania utilization management reforms.
4. Pennsylvania Insurance Department claim denial statistics cited in legislative materials. More than 3 million individual-market claims were denied in Pennsylvania during 2024.